Dr. Drazer's laboratory research focuses on determining the mechanisms that drive hereditary blood and cancer syndromes, with a particular emphasis on developing "high fidelity" cellular and mouse models of these disorders. He is also involved in the discovery of novel hereditary blood and cancer syndromes. His clinical research is largely focused on optimizing the care of people with hereditary blood and cancer syndromes, including the development of clinical bioinformatics pipelines that improve the diagnosis of patients with these syndromes. He is a member of multiple clinical disease groups at the University of Chicago.
Indiana University
Bloomington
BA, BS - Biochemistry; Biology; English
University of Chicago
Chicago
PhD - Human Genetics
University of Chicago
Chicago
MD - Medicine
University of Chicago
Chicago
Residency - Internal Medicine
University of Chicago
Chicago
Fellowship - Hematology/Oncology
Predisposition to hematopoietic malignancies by deleterious germline CHEK2 variants.
Predisposition to hematopoietic malignancies by deleterious germline CHEK2 variants. Leukemia. 2025 May 07.
PMID: 40335619
ANKRD26-related Thrombocytopenia 2 with a Baseline Increase in Blasts: Implications for Clinical Surveillance.
ANKRD26-related Thrombocytopenia 2 with a Baseline Increase in Blasts: Implications for Clinical Surveillance. Blood. 2025 May 07.
PMID: 40331912
Germ line JAK2 variants and hereditary blood cancers.
Germ line JAK2 variants and hereditary blood cancers. Blood Adv. 2025 Apr 08; 9(7):1585-1586.
PMID: 40152887
Treatment of Pleural Mesothelioma: ASCO Guideline Clinical Insights.
Treatment of Pleural Mesothelioma: ASCO Guideline Clinical Insights. JCO Oncol Pract. 2025 Mar 07; OP2500035.
PMID: 40053896
Treatment of Pleural Mesothelioma: ASCO Guideline Update.
Treatment of Pleural Mesothelioma: ASCO Guideline Update. J Clin Oncol. 2025 Mar 10; 43(8):1006-1038.
PMID: 39778125
Expedited evaluation of hereditary hematopoietic malignancies in the setting of stem cell transplantation.
Expedited evaluation of hereditary hematopoietic malignancies in the setting of stem cell transplantation. Haematologica. 2024 Nov 01; 109(11):3739-3744.
PMID: 38618681
Germ line ERG haploinsufficiency defines a new syndrome with cytopenia and hematological malignancy predisposition.
Germ line ERG haploinsufficiency defines a new syndrome with cytopenia and hematological malignancy predisposition. Blood. 2024 10 24; 144(17):1765-1780.
PMID: 38991192
FLT3 Agonists and Secondary Hematopoietic Malignancies: A Potential Class Effect.
FLT3 Agonists and Secondary Hematopoietic Malignancies: A Potential Class Effect. Clin Cancer Res. 2024 Jul 15; 30(14):2857-2859.
PMID: 38652676
Real world predictors of response and 24-month survival in high-grade TP53-mutated myeloid neoplasms.
Real world predictors of response and 24-month survival in high-grade TP53-mutated myeloid neoplasms. Blood Cancer J. 2024 06 18; 14(1):99.
PMID: 38890297
ASO Author Reflections: Venous Thromboembolism in Peritoneal Mesothelioma.
ASO Author Reflections: Venous Thromboembolism in Peritoneal Mesothelioma. Ann Surg Oncol. 2024 Jun; 31(6):3785-3786.
PMID: 38502295